To the editor: Pure erythroid leukemia[1][1] (PEL), or AML-M6b, is a rare form of leukemia characterized by proliferation of >80% undifferentiated or pronormoblastic immature cells committed exclusively to the erythroid lineage.[2][2] Previous reports have described the aggressive nature of
No takes yet. Share an insight, caveat, or question.
Montalban‐Bravo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: